Summary
The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S [chimpanzee adenovirus-severe acute respiratory syndrome-coronavirus-2-S]) in the upper and lower respiratory tracts of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tracts after SARS-CoV-2 challenge. As ChAd-SARS-CoV-2-S confers protection in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.
【저자키워드】 SARS-CoV-2, Vaccine, immunogenicity, Immunity, protection, non-human primates, adenoviral vector, mucosal, 【초록키워드】 COVID-19, coronavirus disease, neutralizing antibody, Efficacy, ACE2, pandemic, SARS-COV-2 infection, Infection, Transmission, Protein, mice, humans, receptor, disease, T cell response, intranasal, Protective, rhesus macaque, dose, Lower respiratory tract, human Angiotensin-converting enzyme, Administered, pre-fusion, Prevent, limit, immunized, described, intranasally, required, induce, expressing, chimpanzee adenovirus-vectored vaccine, intrabronchial, 【제목키워드】 SARS-COV-2 infection, intranasal, rhesus macaque, dose, PROTECT, chimpanzee adenovirus-vectored vaccine,